Wayne Shaw

11.7k total citations · 4 hit papers
36 papers, 8.3k citations indexed

About

Wayne Shaw is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Wayne Shaw has authored 36 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Surgery and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Wayne Shaw's work include Diabetes Treatment and Management (28 papers), Pancreatic function and diabetes (17 papers) and Diabetes Management and Research (12 papers). Wayne Shaw is often cited by papers focused on Diabetes Treatment and Management (28 papers), Pancreatic function and diabetes (17 papers) and Diabetes Management and Research (12 papers). Wayne Shaw collaborates with scholars based in United States, United Kingdom and Australia. Wayne Shaw's co-authors include Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, David R. Matthews, Greg Fulcher, Mehul Desai, Ngozi Erondu, Gordon Law and Terrance D. Barrett and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Finance.

In The Last Decade

Wayne Shaw

34 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

2017 5.4k citations Bruce Neal, Vlado Perkovic et al. New England Journal of Medicine profile →
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

2018 468 citations Vlado Perkovic, Dick de Zeeuw et al. The Lancet Diabetes & Endocrinology profile →
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

2017 375 citations Kenneth W. Mahaffey, Bruce Neal et al. Circulation profile →
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

2018 368 citations Karin Rådholm, Gemma A. Figtree et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wayne Shaw United States	24	7.0k	3.0k	2.7k	1.9k	986	36	8.3k
Avivit Cahn Israel	29	7.7k 1.1×	3.0k 1.0×	3.1k 1.1×	2.0k 1.1×	1.1k 1.1×	113	9.3k
Mehul Desai United States	30	7.8k 1.1×	3.4k 1.1×	3.3k 1.2×	2.0k 1.0×	1.1k 1.1×	49	9.5k
Eri Kato Japan	15	6.0k 0.9×	2.5k 0.8×	2.5k 0.9×	2.0k 1.1×	926 0.9×	47	7.5k
Thomas A. Zelniker United States	21	6.8k 1.0×	2.8k 0.9×	2.8k 1.0×	2.5k 1.3×	1.3k 1.3×	68	8.8k
Hans J. Woerle Germany	17	8.5k 1.2×	3.5k 1.2×	3.5k 1.3×	2.4k 1.3×	931 0.9×	26	10.0k
Julia Kuder United States	30	4.9k 0.7×	3.6k 1.2×	1.9k 0.7×	3.2k 1.7×	973 1.0×	60	8.8k
Michael G. Silverman United States	22	4.5k 0.6×	2.6k 0.9×	1.9k 0.7×	2.0k 1.1×	706 0.7×	44	6.8k
Stefan Hantel Germany	27	9.4k 1.3×	4.7k 1.6×	4.0k 1.5×	4.9k 2.6×	1.2k 1.2×	63	13.8k
Steven P. Marso United States	31	9.0k 1.3×	3.2k 1.1×	3.4k 1.2×	2.2k 1.2×	509 0.5×	74	11.2k
Michaela Mattheus Germany	28	11.5k 1.6×	4.9k 1.6×	4.6k 1.7×	2.9k 1.6×	1.4k 1.5×	84	13.7k

Countries citing papers authored by Wayne Shaw

Since Specialization

Citations

This map shows the geographic impact of Wayne Shaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wayne Shaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wayne Shaw more than expected).

Fields of papers citing papers by Wayne Shaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wayne Shaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wayne Shaw. The network helps show where Wayne Shaw may publish in the future.

Co-authorship network of co-authors of Wayne Shaw

This figure shows the co-authorship network connecting the top 25 collaborators of Wayne Shaw. A scholar is included among the top collaborators of Wayne Shaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wayne Shaw. Wayne Shaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gogate, Jagadish, et al.. (2025). Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes. Annals of Internal Medicine. 178(9). 1217–1226.

Khan, Muhammad Shahzeb, James L. Januzzi, Yuxi Liu, et al.. (2024). Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events. Journal of Cardiac Failure. 30(12). 1544–1551. 2 indexed citations

Vaduganathan, Muthiah, Naveed Sattar, Javed Butler, et al.. (2022). Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology. 79(5). 432–444. 27 indexed citations

Januzzi, James L., Jingwei Li, Wayne Shaw, et al.. (2020). Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide. Journal of the American College of Cardiology. 76(18). 2076–2085. 53 indexed citations

Arnott, Clare, Brendon L. Neuen, Hiddo J.L. Heerspink, et al.. (2020). The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International Journal of Cardiology. 318. 126–129. 23 indexed citations

Ohkuma, Toshiaki, Luc Van Gaal, Wayne Shaw, et al.. (2019). Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes Obesity and Metabolism. 22(4). 530–539. 22 indexed citations

Zhou, Zien, Richard I. Lindley, Karin Rådholm, et al.. (2018). Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke. 50(2). 396–404. 53 indexed citations

Rådholm, Karin, Gemma A. Figtree, Vlado Perkovic, et al.. (2018). Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation. 138(5). 458–468. 368 indexed citations breakdown →

Perkovic, Vlado, Dick de Zeeuw, Kenneth W. Mahaffey, et al.. (2018). Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. The Lancet Diabetes & Endocrinology. 6(9). 691–704. 468 indexed citations breakdown →

10.

Mahaffey, Kenneth W., Bruce Neal, Vlado Perkovic, et al.. (2017). Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation. 137(4). 323–334. 375 indexed citations breakdown →

11.

Neal, Bruce, Vlado Perkovic, Kenneth W. Mahaffey, et al.. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 377(7). 644–657. 5379 indexed citations breakdown →

12.

Neal, Bruce, Vlado Perkovic, Kenneth W. Mahaffey, et al.. (2017). Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials. Diabetes Obesity and Metabolism. 19(7). 926–935. 79 indexed citations

13.

Gilbert, Richard E., Matthew R. Weir, Paola Fioretto, et al.. (2016). Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes. 40(3). 247–257. 12 indexed citations

14.

Rosenthal, Norm, Gary Meininger, Kirk Ways, et al.. (2015). Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences. 1358(1). 28–43. 79 indexed citations

15.

Fulcher, Greg, David R. Matthews, Vlado Perkovic, et al.. (2015). Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy. 6(3). 289–302. 34 indexed citations

16.

Sinclair, Alan J., Bruce W. Bode, Stewart B. Harris, et al.. (2014). Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocrine Disorders. 14(1). 37–37. 73 indexed citations

17.

Hogg, Ronald J., Ángela Delucchi, Thomas G. Wells, et al.. (2007). A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatric Nephrology. 22(5). 695–701. 24 indexed citations

18.

Wells, Thomas G., et al.. (2002). A Double‐Blind, Placebo‐Controlled, Dose‐Response Study of the Effectiveness and Safety of Enalapril for Children with Hypertension. The Journal of Clinical Pharmacology. 42(8). 870–880. 103 indexed citations

19.

Wells, Thomas G., Ronald J. Hogg, Abdullah Şakarcan, et al.. (2001). The Pharmacokinetics of Enalapril in Children and Infants with Hypertension. The Journal of Clinical Pharmacology. 41(10). 1064–1074. 39 indexed citations

20.

Morse, Dale L. & Wayne Shaw. (1988). Investing in Bankrupt Firms. The Journal of Finance. 43(5). 1193–1193. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact